Portfolio Alerts Watch List Cart

Healthcare

Refine Search


Product Compare (0)
A
Amrutanjan Health Care Ltd
Score 68/100• Decent
Amrutanjan Health Care Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
Company’s Health86/100
Valuation 20/100 · PB 6.4072
Technical Avoid
1M 2.904% 6M 3.347% 1Y -4.711%
Confidence100%
Low leverage (D/E)No promoter pledge
#106
View details ➜
A
Alembic Pharmaceuticals Ltd
Score 68/100• Decent
Alembic Pharmaceuticals shows potential for growth but faces challenges in profitability and market competition.
Company’s Health81/100
Valuation 40/100 · PB 3.3991
Technical Avoid
1M -0.332% 6M 2.279% 1Y -20.503%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#107
View details ➜
A
Akums Drugs and Pharmaceuticals Ltd
Score 68/100• Decent
Akums Drugs and Pharmaceuticals Ltd shows potential for growth, but faces challenges in profitability and market competition.
Company’s Health79/100
Valuation 60/100 · PB 2.3026
Technical Avoid
1M 4.886% 6M -10.983% 1Y -45.273%
Confidence100%
Low leverage (D/E)No promoter pledge
#108
View details ➜
G
GlaxoSmithKline Pharmaceuticals Ltd
Score 68/100• Decent
GlaxoSmithKline Pharmaceuticals Ltd shows decent fundamentals but faces challenges in profitability and market sentiment. It is a stable player in a growing sector, but caution is advised due to valuation concerns and execution risks.
Company’s Health84/100
Valuation 20/100 · PB 22.7338
Technical Avoid
1M -1.684% 6M -8.209% 1Y -3.453%
Confidence100%
Low leverage (D/E)No promoter pledge
#109
View details ➜
G
Gland Pharma Ltd
Score 68/100• Decent
Gland Pharma shows potential for growth but faces challenges in profitability and market competition.
Company’s Health86/100
Valuation 40/100 · PB 3.4729
Technical Avoid
1M -4.327% 6M 37.435% 1Y 16.825%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROE
#110
View details ➜
F
Fischer Medical Ventures Ltd
Score 68/100• Decent
Fischer Medical Ventures Ltd shows potential but faces several challenges that may hinder growth and profitability.
Company’s Health73/100
Valuation 20/100 · PB 22.5942
Technical Watch
1M 5.388% 6M 44.634% 1Y 86.693%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#111
View details ➜
F
F D C Ltd
Score 68/100• Decent
F D C Ltd shows potential for growth in a stable sector, but faces challenges in profitability and valuation metrics.
Company’s Health86/100
Valuation 40/100 · PB 3.2878
Technical Avoid
1M 2.229% 6M 8.926% 1Y -15.717%
Confidence100%
Low leverage (D/E)No promoter pledge
#112
View details ➜
D
Dr. Agarwal's Health Care Ltd
Score 68/100• Decent
Dr. Agarwal's Health Care Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should proceed with caution.
Company’s Health65/100
Valuation 20/100 · PB 8.307
Technical Avoid
1M 2.702% 6M 43.17% 1Y 26.043%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#113
View details ➜
C
Concord Drugs Ltd
Score 68/100• Decent
Concord Drugs Ltd shows potential but faces significant challenges in growth and profitability metrics.
Company’s Health71/100
Valuation 60/100 · PB 2.024
Technical Watch
1M 0.15% 6M 130.518% 1Y 83.568%
Confidence100%
No promoter pledgeReasonable PB valuation
Weak ROEThin margins
#114
View details ➜
C
Caplin Point Laboratories Ltd
Score 68/100• Decent
Caplin Point Laboratories Ltd shows potential for growth but faces challenges in profitability and valuation metrics.
Company’s Health100/100
Valuation 20/100 · PB 5.3533
Technical Avoid
1M 2.862% 6M 7.818% 1Y -0.128%
Confidence100%
Low leverage (D/E)No promoter pledge
#115
View details ➜
B
Brooks Laboratories Ltd
Score 68/100• Decent
Brooks Laboratories Ltd shows potential in a growing sector, but faces challenges in growth consistency and profitability metrics.
Company’s Health55/100
Valuation 40/100 · PB 3.3306
Technical Avoid
1M -17.251% 6M -15.488% 1Y -20.332%
Confidence100%
Low leverage (D/E)No promoter pledge
Weak ROEThin margins
#116
View details ➜
B
Blue Jet Healthcare Ltd
Score 68/100• Decent
Blue Jet Healthcare Ltd shows potential for growth but faces significant challenges in profitability and execution risks.
Company’s Health100/100
Valuation 20/100 · PB 10.0487
Technical Avoid
1M 1.633% 6M -9.243% 1Y 38.832%
Confidence100%
Low leverage (D/E)No promoter pledge
#117
View details ➜
A
Anlon Healthcare Ltd
Score 68/100• Decent
Anlon Healthcare Ltd shows potential for growth, but faces challenges in valuation and execution risks.
Company’s Health70/100
Valuation 20/100 · PB 8.5001
Technical Avoid
1M -3.79% 6M 40.205% 1Y 40.205%
Confidence100%
No promoter pledgeHealthy profit margins
#118
View details ➜
A
Aditya BSL Nifty Healthcare ETF
Score 68/100• Decent
The Aditya BSL Nifty Healthcare ETF shows potential for growth in a vital sector, but faces challenges in valuation and governance that investors should consider.
Company’s Health0/100
Valuation 0/100 · PB —
Technical Avoid
1M -1.655% 6M 3.336% 1Y -2.998%
Confidence80%
#119
View details ➜
A
Accretion Pharmaceuticals Ltd
Score 68/100• Decent
Accretion Pharmaceuticals Ltd shows potential but faces challenges in growth consistency and valuation metrics.
Company’s Health91/100
Valuation 40/100 · PB 4.3548
Technical Avoid
1M -1.522% 6M -27.788% 1Y -27.788%
Confidence100%
No promoter pledgeDecent revenue growth
#120
View details ➜
Showing 106 to 120 of 301 (21 Pages)